US healthcare giant Johnson & Johnson (NYSE: JNJ) opened nearly 2% lower in Wednesday’s trading after presenting its financial results for the fourth quarter of 2019, and the year as a whole.
The company reported fourth-quarter sales of $20.74 billion, up 1.7% on the same period of 2018 but below the average estimate of Wall Street experts polled by Refinitiv, who had expected $20.8 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze